Abstract Body

Background: We previously characterized the neutralization sensitivity of the nonhuman primate (NHP) challenge stock SIVsmE660 and found the isolate was generally highly neutralization sensitive with a minor population of resistant variants (Lopker et al., J Virol 2013). We hypothesized that incomplete vaccine-mediated protection may result from protection against only the neutralization sensitive fraction of SIVsmE660. Subsequently, a large NHP vaccine study demonstrated incomplete protection from SIVsmE660 challenge and identified genotypic signatures associated with neutralization resistance (Roederer et al., Nature 2014). Here, we perform a phenotypic neutralization sieve analysis of the breakthrough TF viruses of this NHP vaccine study.

Methods: TF Env clones were derived by single genome sequencing of peak plasma vRNA from the breakthrough infections in heterologous Env-immunized animals (n=18 TF Envs) and controls (n=35 TF Envs). Neutralization sensitivity was assessed in a TZM-bl assay with SIV-infected macaque plasmas and a panel of 10 monoclonal antibodies (mAb) targeting V1, V2, V3, V4, CD4bs and CD4i epitopes.

Results: The breakthrough TF Envs from immunized animals were significantly more neutralization resistant to immune plasma and mAbs targeting diverse gp120 epitopes than those from control animals. The maximum reductions in infectivity from plasma were 74.6% in control Envs, and 40.3% in vaccine Envs (p<0.0001, Mann-Whitney). The majority of vaccine TF Envs (13/18, 72%) were highly neutralization resistant (IC50<1:10), compared with the fraction comprising the control TF Envs (6/35, 17%, p=0.0002) and the SIVsmE660 isolate (10%, p=0.0002). The genotypic signatures of resistance identified in the Roederer study were highly predictive of phenotypic neutralization sensitivity.

Conclusions: We demonstrate a phenotypic neutralization sieve effect in a large NHP vaccine challenge study with substantial enrichment for neutralization resistant viruses in the breakthrough infections of vaccinated animals. These findings support our hypothesis that incomplete vaccine-mediated protection results from selection against the highly neutralization sensitive component of the SIVsmE660 isolate. Further, we corroborate the genetic signatures of SIVsmE660 neutralization sensitivity predicted in the parent study. Together, these findings demonstrate proof-of-concept that phenotypic neutralization sieve analyses may be useful in assessment of vaccine trial outcomes and correlates analysis.